Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.

Schneiderman RS, Shmueli E, Kirson ED, Palti Y.

BMC Cancer. 2010 May 23;10:229. doi: 10.1186/1471-2407-10-229.

2.

[Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].

Zhang YH, Li G, Yu J, Xu MS, Liu ZX.

Zhonghua Zhong Liu Za Zhi. 2011 Sep;33(9):654-60. Chinese.

PMID:
22340044
3.

Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.

Liu F, Fan D, Qi J, Zhu H, Zhou Y, Yang C, Zhu Z, Xiong D.

Life Sci. 2008 Sep 26;83(13-14):496-501. doi: 10.1016/j.lfs.2008.07.017. Epub 2008 Aug 3.

PMID:
18725232
4.

Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.

Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L.

Oncotarget. 2015 Dec 29;6(42):44643-59. doi: 10.18632/oncotarget.5989.

5.

Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.

Coley HM, Labeed FH, Thomas H, Hughes MP.

Biochim Biophys Acta. 2007 Apr;1770(4):601-8. Epub 2006 Dec 16.

PMID:
17270349
6.
7.

Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW.

Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499. Erratum in: Cancer Res. 2008 Dec 15;68(24):10387.

8.

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.

Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.

PMID:
19232821
9.

β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.

Teng YN, Sheu MJ, Hsieh YW, Wang RY, Chiang YC, Hung CC.

Phytomedicine. 2016 Mar 15;23(3):316-23. doi: 10.1016/j.phymed.2016.01.008. Epub 2016 Feb 6.

PMID:
26969385
10.

Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.

Jovelet C, Bénard J, Forestier F, Farinotti R, Bidart JM, Gil S.

Eur J Pharm Sci. 2012 Aug 15;46(5):484-91. doi: 10.1016/j.ejps.2012.03.012. Epub 2012 Mar 30.

PMID:
22484209
11.

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS.

Cancer Res. 2007 Nov 15;67(22):11012-20.

12.

Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.

Stein U, Lage H, Jordan A, Walther W, Bates SE, Litman T, Hohenberger P, Dietel M.

Int J Cancer. 2002 Feb 20;97(6):751-60.

13.

Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.

Zhang Y, Wang H, Wei L, Li G, Yu J, Gao Y, Gao P, Zhang X, Wei F, Yin D, Zhou G.

Breast Cancer Res Treat. 2010 Oct;123(3):679-89. doi: 10.1007/s10549-009-0660-2. Epub 2009 Dec 6.

PMID:
19967559
14.

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.

Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV.

Br J Cancer. 2008 May 6;98(9):1515-24. doi: 10.1038/sj.bjc.6604334. Epub 2008 Apr 1.

15.

MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).

Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai XF, Yu ZJ, Wu HZ, Sun ML, Song ZG, Wei MJ.

Cancer Lett. 2013 Oct 1;339(1):107-15. doi: 10.1016/j.canlet.2013.07.016. Epub 2013 Jul 20.

PMID:
23879965
16.

Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.

Chen Y, Scully M, Petralia G, Kakkar A.

Cancer Biol Ther. 2014 Jan;15(1):135-45. doi: 10.4161/cbt.27148. Epub 2013 Nov 19.

17.

Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.

van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovée JV.

Ann Oncol. 2012 Jun;23(6):1617-26. doi: 10.1093/annonc/mdr512. Epub 2011 Nov 23.

PMID:
22112972
18.

Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.

Elahian F, Kalalinia F, Behravan J.

Drug Chem Toxicol. 2010 Apr;33(2):113-9. doi: 10.3109/01480540903390000.

PMID:
20307139
19.

Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.

Hembruff SL, Laberge ML, Villeneuve DJ, Guo B, Veitch Z, Cecchetto M, Parissenti AM.

BMC Cancer. 2008 Nov 3;8:318. doi: 10.1186/1471-2407-8-318.

20.

Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.

Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, Chung HY, Kim HS.

Biochim Biophys Acta. 2014 Jan;1840(1):615-25. doi: 10.1016/j.bbagen.2013.10.023. Epub 2013 Oct 24.

PMID:
24161697

Supplemental Content

Support Center